Scarica l'app Stockscreener
23.34
1.52%
0.35
Dopo l'orario di chiusura:
23.34
Xencor Inc Borsa (XNCR) Ultime notizie
Do Xencor’s (XNCR) Mixed 2026 Loss Trends Hint at Shifting Cost Discipline? - simplywall.st
Johnson & Johnson Purchases New Shares in Xencor, Inc. $XNCR - MarketBeat
Industry Analysts Just Made A Huge Upgrade To Their Xencor, Inc. (NASDAQ:XNCR) Revenue Forecasts - simplywall.st
Analysts' Revenue Estimates For Xencor, Inc. (NASDAQ:XNCR) Are Surging Higher - Moomoo
(XNCR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Biotech Stocks At 52-Week HighsBIVI +22%, XNCR, ANRO, HAE, ACAD - RTTNews
Xencor (NASDAQ:XNCR) Hits New 1-Year HighHere's What Happened - MarketBeat
Xencor stock hits 52-week high at 21.99 USD By Investing.com - Investing.com South Africa
Xencor stock hits 52-week high at 21.99 USD - Investing.com
Xencor Inc (XNCR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cantor Fitzgerald Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Analysts Are Upgrading Xencor, Inc. (NASDAQ:XNCR) After Its Latest Results - webull.com
How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First‑Half Deficit - Yahoo Finance
BofA Securities Maintains Xencor(XNCR.US) With Hold Rating, Raises Target Price to $20 - Moomoo
Xencor (NASDAQ:XNCR) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Xencor Inc (XNCR) Stock News Today - TradingKey
Xencor, Inc. Stock 12‑Month Price Target Raised to $29, Implies 45% Upside - TradingView
Xencor, Inc. (XNCR) Stock Report: A Biotech Innovator With 40.83% Upside Potential - DirectorsTalk Interviews
Barclays Reaffirms Their Buy Rating on Xencor (XNCR) - theglobeandmail.com
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Xencor: Q2 Earnings Snapshot - AOL.com
Cantor Fitzgerald Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $44 - Moomoo
XENCOR Maintains Outperform Rating -- Price Target Raised to $20 - GuruFocus
Truist Financial Maintains Xencor(XNCR.US) With Buy Rating - Moomoo
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results - The National Law Review
Wedbush Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Xencor (NASDAQ:XNCR) Surges: What Comes Next? - Kalkine Media
Does Xencor’s Mixed 2026 Loss Trend Reshape the Investment Narrative Around XNCR’s R&D Priorities? - simplywall.st
Xencor (NASDAQ:XNCR) Price Target Raised to $30.00 - MarketBeat
Xencor (NASDAQ:XNCR) Hits New 52-Week High Following Better-Than-Expected Earnings - marketbeat.com
Wedbush Adjusts Price Target on Xencor to $30 From $26, Maintains Outperform Rating - marketscreener.com
RBC Capital Adjusts PT on Xencor to $20 From $19, Maintains Outperform Speculative Risk Rating - marketscreener.com
Xencor (NASDAQ:XNCR) Price Target Raised to $44.00 at Cantor Fitzgerald - MarketBeat
Xencor Inc (XNCR) SWOT Analysis: Financial Challenges and Strate - GuruFocus
Xencor Inc earnings beat by $0.51, revenue topped estimates - Investing.com
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo! Finance Canada
Xencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.51 EPS - MarketBeat
Xencor, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
XENCOR ($XNCR) Releases Q2 2026 Earnings - Quiver Quantitative
Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments - TradingView
Xencor Inc 2Q 2026: Revenue $51.22M, EPS ($0.29) — 10-Q Summary - TradingView
Xencor (NASDAQ: XNCR) nets $105M Alexion settlement as Q2 2026 loss hits $21.7M - Stock Titan
Xencor reports Q2 2026 revenue $51.2M, net loss $21.7M; cash $486.4M - TradingView
Earnings Flash (XNCR) Xencor, Inc. Reports Q2 Revenue $51.2M, vs. FactSet Est of $18.9M - marketscreener.com
BRIEF-Xencor Q2 EPS USD -0.29 - TradingView
Xencor, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Xencor Reports Second Quarter 2026 Financial Results - Yahoo Finance
Xencor faces earnings test after revenue miss rocks biotech By Investing.com - Investing.com Australia
Xencor faces earnings test after revenue miss rocks biotech - in.investing.com
Xencor (NASDAQ:XNCR) Trading Down 3.9%Here's Why - MarketBeat
(XNCR) Risk Channels and Responsive Allocation - Stock Traders Daily
Xencor Inc (XE9.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Xencor (XNCR) Receives a Buy from Wedbush - The Globe and Mail
Xencor, Inc. (XNCR) Investor Outlook: 31.84% Potential Upside In Biotech Innovation - DirectorsTalk Interviews
Barclays Remains a Buy on Xencor (XNCR) - The Globe and Mail
Xencor stock hits 52-week high at 21.34 USD By Investing.com - Investing.com Canada
Wedbush Reiterates Outperform Rating for Xencor (NASDAQ:XNCR) - MarketBeat
Xencor settles Ultomiris royalty dispute for $105 million By Investing.com - Investing.com Nigeria
Xencor To Receive $105 Million From Alexion To Resolve Ultomiris® U.S. Royalty Matter - tradingview.com
Xencor Reaches $105 Million Ultomiris Royalty Settlement With Alexion; U.S. Royalties End - TradingView
Xencorto Continue Receiving Royalties on E - Moomoo
EcoR1 Capital LLC Cuts Stock Holdings in Xencor, Inc. $XNCR - MarketBeat
Xencor Inc (XNCR) Income Statement - TradingKey
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):